Skip to main content

Table 2 Pre- and post-radiotherapy findings of studied patients compared with healthy levels

From: Changes in plasma EBV-DNA and immune status in patients with nasopharyngeal carcinoma after treatment with intensity-modulated radiotherapy

Parameters HD Pre Post P 1 P 2 OR 95%CI
N
(106/ml)
3.30
(2.00–5.90)
3.90
(1.70–13.20)
3.31
(0.95–23.49)
0.06 0.03 0.46 (0.18, 1.15)
L
(106/ml)
2.05
(1.00–3.50)
1.30
(0.20–6.00)
0.43
(0.12–2.32)
0.00 0.00 29.71 (3.68, 239.94)
NLR
(106/ml)
1.60
(0.90–3.30)
2.47
(1.29–29.50)
8.24
(1.34–68.21)
0.00 0.00 0.19 (0.06, 0.55)
EBV DNA
(copies/ml)
56.11
(0.00–3213.50)
1132.56
(0.00–19065.22)
35.67
(0.00–5678.50)
0.00 0.00 0.02 (0.00, 0.20)
CD4+
(106/ml)
0.70
(0.18–1.20)
0.37
(0.05–1.09)
0.07
(0.00–073)
0.00 0.00 9.50 (2.81, 32.10)
Treg
(106/ml)
0.08
(0.04–0.23)
0.09
(0.01–0.26)
0.02
(0.00–0.16)
0.68 0.00 0.86 (0.35, 2.10)
CD8+
(106/ml)
8.49
(3.02–14.85)
3.42
(0.00–7.16)
0.22
(0.00–0.75)
0.00 0.00 20.06 (4.21, 95.56)
CD8+PD1+
(106/ml)
0.19
(0.05–0.45)
0.13
(0.03–0.58)
0.05
(0.01–0.19)
0.02 0.00 3.17 (1.21, 8.30)
  1. N absolute neutrophil count, L absolute lymphocyte count, NLR neutrophil lymphocyte ratio, Treg CD4+CD25+CD127low, P1 Healthy Donor& Pre-radiotherapy, P2 Pre-radiotherapy &Post-radiotherapy, OR the odds ratio, 95%CI 95% confidence intervals